Teva Completes ‘Digihaler Family’
After Announcing Two Further Digital Inhaler Launches
Executive Summary
Teva has completed its portfolio of digital inhalers by launching a further two products, AirDuo Digihaler (fluticasone propionate/salmeterol) and ArmonAir Digihaler (fluticasone propionate), in the US. The pair join the firm’s previously launched ProAir Digihaler (albuterol sulfate).
You may also be interested in...
Teva Moves Ahead With Digital Respiratory Initiative
Teva is expanding its digital health collaboration with Rimidi by implementing a respiratory monitoring program for its Digihalers with California’s Desert Oasis Healthcare.
Teva To Advance Digihaler Data Ecosystem With Rimdi And HealthSnap
Teva’s new partnerships will make patient data from its digital inhalers more accessible to healthcare providers, potentially placing Teva’s asthma platform at the forefront of emerging treatment paradigms.
Teva Strikes Digital Deal With Amazon And Onica
To boost the technology used in its digihaler family of inhalers, Teva has partnered with Amazon Web Services and Onica, a Rackspace Technology company. With this collaboration, Teva aims to protect patients’ information and ensure data security.